February 23, 2024


Technology/Tech News – Get all the latest news on Technology, Gadgets with reviews, prices, features, highlights and specificatio

China plans to mix doses of its vaccines to overcome their low efficacy

The director of the Chinese Center for Disease Control and Prevention (CCCPM) admitted that Chinese vaccines have had limited efficacy and the country is considering mixing doses from different laboratories to enhance their effects. “The existing vaccines do not have a very high protection rate”Gao Fu said about the Chinese vaccines at a conference on Saturday 10 April in the western city of Chengdu. “It is officially planned to use different vaccines from different technologies for the immunization process.”, he added.

Such a move will have dire consequences all over the world, as Chinese vaccines are used in about 20 countries, and in total, more than 70 countries have concluded agreements with Chinese vaccine manufacturers. According to various studies, the most exported Chinese vaccines, those of Sinovac and Sinopharm, have an efficacy between 50% and 80%. In all, more than 115 million doses have already been exported from China, according to data compiled by Airfinity, a British scientific monitoring company.

The article is reserved for our subscribers Read also Vaccines Against Covid-19: Slow Start of the Chinese Campaign, Despite Large Exports

Vaccination with different doses is being studied by experts elsewhere in the world: English researchers in particular are studying the possibility of combining a dose of AstraZeneca vaccine with a dose of Pfizer-BioNTech, with greater efficiency. Professor Gao has also suggested continuing research into messenger RNA vaccines: “Everyone should think about the benefits of vaccines [issus de cette technologie] Of humanity. We must study it carefully and not ignore it because we already have different types of vaccines. “

After a slow start, particularly due to the fact that the virus is under control in the country, China has speeded up its vaccination campaign for a few weeks. By the end of March, 65 million people had received at least the first dose, including 34 million the second. China, so far, only recognizes five vaccines developed in the country, although the Chinese company Fosun Pharma has signed an agreement with Pfizer and BioNTech to produce their vaccine in China, which is pending until approval by the Chinese National Health Commission.

See also  For mRNA technology from the BioNTech team - Budapester Zeitung

“Turn away from the state narrative.”

Gao Fu’s comment came as a surprise as China sought to defend the effectiveness of its vaccines, despite mixed data. In December, the director of the CCCPM participated in questioning the safety of messenger RNA vaccines among the Chinese population, saying that unknown side effects could not be ruled out. Chinese government media and many scientific blogs have also published many articles for this purpose, which is a way of reassuring, empty, about Chinese products, using the most stable technology of inactivated virus. “I was surprised by what Gao said, not because it differs from what we already know, but because it deviates from the state’s narrative about the effectiveness of vaccines. The Chinese versus Western vaccines.”Huang Yanzhong, president of international health affairs at the Council on Foreign Relations (CFR), a US think tank, commented on Twitter.

You have 47.07% of this article left to read. The rest is for subscribers only.